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Abstract
The clinical indications and guidelines for low-
density lipoprotein (LDL)-apheresis set by the 1st 
Italian Consensus Conference held in Ostuni in 1990 
and completed in 1992, but never published, are 
reported schematically. In 1994, within the Project 
"Prevention and control of the factors of the disease 
(FATMA)" by the Italian National Research Council, 
subproject 8 "Control of cardiovascular disease", a 
"Hearing on therapeutic apheresis: need for a target-
oriented project" was organised. The meeting was the 
last scientific initiative on LDL-apheresis supported 
by public funds in Italy. After roughly two decades 
of use of LDL-apheresis, new guidelines were 
required based on the latest scientific evidence. In 
2006, the Italian multicentre study on LDL-apheresis 
Working Group (IMSLDLa-WP), a scientific 
initiative at national level, was developed. It initially 
gathered together 19 Italian centres qualified for the 
application of lipid apheresis and LDL-apheresis 
(2007-2008), then 23 in 2010, located in the north, 
south, centre of Italy and in Sicily and Sardinia. The 
multicentre study aimed to validate the protocol for 
selecting patients and to create a network between 
the Italian centres. A secondary objective was the 
creation of a database of patients with familial 
hypercholesterolaemia and other severe forms of 
dyslipidaemia undergoing treatment with LDL-
apheresis using the available techniques. Since LDL-
apheresis has multidisciplinary treatment indications, 
the agreement on the new guidelines was reached 
through a panel of experts, of different medical 
and surgical specialties, with scientific and medical 
interest in the treatment indications, application and 
development of LDL-apheresis. The initiatives of 
the IMSLDLa-WP led to the 2nd Italian Consensus 
Conference on LDL-apheresis held in Rome in 2009. 
The previous and most recent guidelines are reported 
here synoptically. 
Keywords: Italian Consensus Conference on LDL-
apheresis, lipoprotein apheresis, MTP inhibitor, 
mipomersen, PCSK9 inhibitors.
The 1st Italian Consensus Conference on LDL-
apheresis (Ostuni, Italy, 1990)
Background - part one
The clinical criteria and guidelines for low-density 
lipoprotein (LDL)-apheresis set by the 1st Italian Consensus 
Conference, held in Ostuni in 1990, and completed 
in 1992, are reported in Table I. Given the scientific 
evidence collected in more than two decades of use of 
LDL-apheresis, updated guidelines are required. In 1994, 
within the Project "Prevention and control of the factors 
of the disease (FATMA)" by the Italian National Research 
Council, directed by Prof. Giorgio Ricci, a "Hearing on 
therapeutic apheresis: need for a target-oriented project" 
was organised1. The last scientific initiative on LDL-
apheresis, of institutional relevance, financed with public 
funds, emerged from this meeting. The initiative was 
realised within subproject 8, "Control of the cardiovascular 
disease", directed by Prof. Cesare Dal Palù. 
This meeting provided consensus on the following.
The patient to treat with LDL-apheresis
Introduction
- It has already been clearly demonstrated that 
LDL plasma concentration is one of the most 
important causes of atherosclerosis and subsequent 
cardiovascular complications, in particular, 
coronary complications. Patients affected by serious 
hyperlipoproteinaemia (often with a monogenic or 
polygenic basis) present with a history of previous 
Table I - LDL-apheresis Interdisciplinary National 
Committee Guidelines (1990-1992).
The indications for treatment with LDL-apheresis are the following: 
- Homozygous familial hypercholesterolaemia (FH) and double 
heterozygous FH: early start of therapy for all the patients.
- Primary hypercholesterolaemia: patients with at least two of the 
following needs for treatment: 
 1) no response to multiple pharmacological therapies and 
dietary therapy; 
 2) severe asymptomatic and symptomatic atheromasia, 
including previous acute myocardial infarction;
 3) coronary angioplasty, aortocoronary bypass, or other 
major vascular surgery, when pharmacological aids do not 
guarantee bypass patency with reasonable certainty; 
 4) heart transplant.
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coronary atherosclerotic disease (and/or carotid or 
peripheral disease), even in paediatric age; their rates 
of fatal and non-fatal coronary or cerebral events are 
between five to 100 times higher than those observed 
in the general population.
- It has also been confirmed that the increase of LDL 
and/or other variations of lipoproteins, such as very 
low-density lipoproteins (VLDL), b-VLDL and 
lipoprotein (a) in plasma can influence to varying 
degrees the progression of atherosclerotic lesions 
and clinical vasculopathy (microviscosity and 
fluid-dynamic characteristics of blood, endothelial 
integrity, cellular and immune system modulation, 
subendothelial lipid deposits, coagulatory effects, 
platelet activity and fibrinolysis, etc.).
- Numerous studies of statins indicate that a reduction 
in the mean level of total cholesterol and, in particular, 
that carried by LDL, causes a decrease in myocardial 
infarctions both in hyperlipoproteinaemic subjects 
as well as in the general population. In addition, 
very recent studies document the ability of these 
drugs to lead to the regression of atherosclerotic 
coronary lesions by reducing LDL-cholesterol plasma 
concentrations.
LDL-apheresis
- LDL-apheresis is a new procedure for selectively 
removing LDL from blood, which, briefly, is based 
upon the interaction of LDL with sub-layers capable 
of isolating atherogenic lipoproteins. LDL-apheresis 
is potentially applicable in the removal of other 
lipoproteins from blood [i.e. VLDL, Lp(a)].
- By means of LDL-apheresis it is possible to reduce 
plasma concentrations of LDL-cholesterol markedly, 
in a very brief time. During a 2- to 4-hour session up to 
10 grams of LDL-cholesterol can be removed, reducing 
LDL-cholesterol levels by as much as 70-85%.
- Periodic repetition of apheresis sessions (possibly 
also combined with pharmacological therapy): 
 a) maintains a mean LDL-cholesterol level much lower 
than that achieved with diet or drug therapy and,
 b) improves, in brief or even very brief time, the 
fluid-dynamic characteristics of blood. It is for this 
reason that this method is proposed as an option to 
prevent vascular complications of atherosclerosis, 
and also to interrupt the progression or initiate the 
regression of atherosclerotic lesions.
- Several methods are available to selectively remove 
various lipoproteins from plasma [LDL, VLDL, 
Lp(a)]: apheresis by means of monoclonal or 
polyclonal antibodies, attached to a fixed phase; 
selective apheresis by means of precipitation with 
sodium heparin; apheresis by means of chemical 
absorption, using dextrane sulphate or other absorbing 
chemicals; apheresis by means of semi-selective 
absorption on cellulose diacetate; and others as well.
- Selective methods for filtration include Liposorber® 
(dextransulphate on cellulose), the heparin-induced 
extracorporeal lipoprotein precipitation (HELP) system, 
and direct absorption of lipoprotein (DALI). Semi-
selective filtration can be achieved via various systems 
for cascade filtration or double filtration. The Consensus 
group noted that severe hypertriglyceridaemia and 
hyperchylomicronaemia with associated acute 
pancreatitis can be treated by means of conventional, 
non-selective plasma-exchange.
Indications
- Homozygous or double heterozygous familial 
hypercholesterolaemia (FH).
- H e t e r o z y g o u s  F H  a n d  o t h e r  g e n e t i c 
hypercholesterolaemias, which meet at least one of 
the following criteria:
 - absence of response to diet and drug therapies;
 - presence of severe atherosclerosis;
 - patients with a coronary-aorta bypass or patients 
who have undergone major vascular surgery 
when the drug therapy does not guarantee 
stabilisation of the ischaemic heart disease.
Contraindications
- Paediatric age (with the exception of homozygous 
and double heterozygous FH).
- All the contraindications of extracorporeal therapies.
- Allergies to the anticoagulant class of drugs, which 
are simultaneously administered intravenously.
- Other factors to be considered contraindicative are: 
advanced age, other concomitant serious illnesses, the 
impossibility of evaluating other risk factors present, and 
the patient's refusal to follow other necessary therapies.
LDL-apheresis: where, how, and when it is to be 
performed
- LDL-apheresis must be performed in centres 
with medical competence in lipid and metabolic 
diseases, and with the ability to monitor the 
cardiovascular condition by invasive and non-
invasive means. Laboratory centres that monitor 
atherogenic lipoprotein fractions should be available, 
and selective techniques of LDL-apheresis must 
be performed by clinicians who are experts in 
extracorporeal circulation.
- LDL-apheresis must be initiated only after appropriate 
diet and drug therapy has been attempted.
- During LDL-apheresis treatment, drug therapy and 
an appropriate diet must be continued.
- It is advisable to eliminate other notable risk factors, 
whenever possible, and cardiological assistance must 
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be guaranteed in order to evaluate positive or negative 
outcomes related to the extracorporeal treatment.
- Only methods that have been evaluated for sufficiently 
long periods of time, and which show no side effects 
to the lipoprotein profile, should be applied.
- A periodic evaluation of the tolerability of the 
treatment is recommended.
- Patients must make an informed decision to undergo 
treatment.
LDL-apheresis end results, timing of treatment and 
its suspension
- The primary objective of apheresis is the maintenance of 
the mean LDL-cholesterol at the lowest possible level. 
- Since the increase in LDL-cholesterol after an LDL-
apheresis treatment session varies among individuals 
(because of genetics, environmental factors, diet and 
drugs), the end result should be one that maintains 
the lowest possible LDL-cholesterol level for the 
individual patient, bearing in mind that all methods of 
prolonging times between sessions should be applied, 
so as to keep costs as low as possible, allow centres 
to treat more individuals, and reduce the burden of 
medical treatment for patients, etc.
- In patients with homozygous FH, and in the more 
serious cases, the timing of treatment should, in any 
case, be a session every 5-10 days (independently of 
the points raised in Section 6.2).
- Every 2-3 years a medical staff, consisting of experts, 
should evaluate the benefits of continuing treatment, 
based upon clinical and coronary outcomes as well 
as tolerance to treatment.
- The decision to suspend apheretic treatment needs 
to be made taking into account lipid, cardiological 
and transfusional issues, and also bearing in mind 
the patient's wishes.
The 2nd Italian Consensus Conference on LDL-
Apheresis (Rome, Italy, 2009)
Background - part two
In 2006 the Italian Multicentre Study on LDL-
apheresis Working Group (IMSLDLa-WP), led to the 
collection of 19 Italian centres in 2007 and 2008 (23 in 
2010) qualified for the application of lipid apheresis and 
LDL-apheresis. These centres were located in the north, 
south, and centre of Italy and in the major islands, Sicily 
and Sardinia. Since LDL-apheresis has multidisciplinary 
treatment indications, agreement on the new guidelines 
was achieved through a panel of interdisciplinary 
experts, representing the different medical and surgical 
specialists with scientific and medical interest in 
extracorporeal treatment, and indications, application 
and development of LDL-apheresis techniques. The 
former guidelines of the LDL-apheresis Interdisciplinary 
National Committee were updated and in 2009 a 2nd 
Italian Consensus Conference on LDL-apheresis was 
held in Rome. The following research group, scientific 
societies, and patient association participated in the event 
and supported a consensus document later published in 
the international literature2: Italian Multicentre Study 
on LDL-apheresis Working Group (IMSDLa-WP), 
Metabolic Diseases and Atherosclerosis Study Group, 
Italian Society for the Study of Arteriosclerosis (Società 
Italiana per lo Studio dell'Aterosclerosi, SISA), Italian 
Society for Haemapheresis (Società Italiana di Emaferesi 
e Manipolazione Cellulare, SIdEM), Italian Society of 
Nephrology (Società Italiana di Nefrologia, SIN), Italian 
Society of Internal Medicine (Società Italiana di Medicina 
Interna, SIMI) and the Italian National Association for 
Familial Hypercholesterolaemia (Associazione Nazionale 
Ipercolesterolemia Familiare,  ANIF). 
This meeting provided consensus on the following.
The patient eligible for treatment with 
lipoprotein-apheresis
The diagnosis of severe dyslipidaemia must be 
clinical and genetic-molecular, and extended to first-
degree relatives. The extension of xanthomatosis, if 
present, must be carefully evaluated. Early initiation 
of treatment with LDL-apheresis/lipid apheresis is 
indispensable to prevent severe malformations of the 
aortic valve and progression of atherosclerotic lesions 
in coronary arteries. Bearing this in mind, it is suggested 
that the treatment of children with homozygous FH 
starts from around 6 years of age. However, precocious 
symptoms and signs are to be considered warnings, 
which compel careful clinical and prognostic evaluation 
of each individual case. Clinically prominent indications 
may lead to earlier treatment with LDL-apheresis/
lipid apheresis. Preliminary non-invasive and invasive 
investigations of cardiovascular profile must not be 
omitted before starting treatment with LDL-apheresis/
lipid apheresis in homozygous FH subjects. The 
cardiovascular follow-up is evermore necessary in order 
to evaluate the efficacy and safety of the treatment over 
time, with particular reference to primary cardiovascular 
endpoints. Aortic and coronary catheterisation and/
or high resolution computed tomography coronary 
angiography, must be carried out serially on a 2-yearly 
basis in patients with documented coronary and/or aortic 
valve lesions, or who have undergone revascularisation 
of the coronary arteries, or who are heading to aortic 
valve replacement3-5. The aorta and leg vessels may also 
be examined. Lp(a) is one of the variables co-related to 
lipid metabolism with prognostic value, and its assay is 
strongly suggested. Indications for apheresis to remove 
Lp(a) were considered. For detailed recommendations, 
see Tables II-VII.
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Table II - LDL-apheresis in dyslipidaemias: clinical 
indications - 2nd Italian Consensus Conference 
on LDL-apheresis (2009).
- Homozygous familial hypercholesterolaemia (FH) and double 
heterozygous (compound) FH. 
- Autosomal recessive FH.
- Heterozygous FH.
- Hyperlipoprotein(a)aemia.
- Severe non-FH hypercholesterolaemia associated with 
progressive coronary artery disease.
- Other genetically determined dyslipidaemias of atherogenic 
nature and high cardiovascular risk profile.
Table III - LDL-apheresis. Other suggested indications 
2nd Italian Consensus Conference on LDL-
apheresis (2009).
- Sudden loss of hearing.
- Cerebrovascular disease.
- Peripheral artery disease.
- Non-arteritic ischaemic optical neuropathy (NAION)19-22. 
Indications for LDL-apheresis in diabetes and pregnancy were also 
given.
Table IV - Clinical and diagnostic protocol in paediatric 
patients eligible for treatment with LDL-
apheresis - 2nd Italian Consensus Conference 
on LDL-apheresis (2009).
The clinical and diagnostic protocol for paediatric patients, as for 
adults, must include:
- genetic-molecular diagnosis through molecular biology techniques;
- objective clinical examination with attention to lesions 
(xanthomas) related to dyslipidaemia;
- stress electrocardiography;
- echocardiography;
- echo colour Doppler of epi-aortic and ilio-femoral vessels;
- aortic and coronary artery catheterisation.
During the cycle of treatment the following are recommended:
- objective clinical examinations every 3 months;
- stress electrocardiography every 6 months;
- echocardiography every year;
- echo colour Doppler of epi-aortic and ilio-femoral vessels, 
every year;
- aortic and coronary artery catheterisation, every 2 years4,23.
For paediatric patients, specialist paediatric and psychological 
support is indispensable. This should be foreseen at the beginning 
and during the entire cycle of treatment. It is also necessary to obtain 
written informed consent with authorising signatures by the parents.
Table VI - Cardiovascular examinations in patients under 
treatment with LDL-apheresis - 2nd Italian 
Consensus Conference on LDL-apheresis (2009).
- Cardiovascular examination and electrocardiography: 
 must be performed before submitting patients to LDL-
apheresis, and later at least once a year (follow-up) to evaluate 
the patient's clinical condition.
- Cardiac echo colour Doppler
 must be performed before submitting patients to LDL-
apheresis, and later every 1-2 years (follow-up). In the case 
of documented lesions (left ventricular impairment, aortic 
supravalvular stenosis, and valvular insufficiency) the 
examination can be repeated more frequently.
- Exercise electrocardiography
 Performed to reveal the possible presence of objective 
findings suggestive of myocardial ischaemia that is not 
associated with angina or anginal equivalent; to be performed 
before submitting patients to LDL-apheresis and later once a 
year (follow-up). When indicated it can be substituted with 
stress myocardial scintigraphy, a pharmacologically-induced 
stress test, or stress echocardiography.
Table VII - Lipid apheresis in severe pancreatitis 
associated with severe hypertriglyceridaemia 
2nd Italian Consensus Conference on LDL-
apheresis (2009).
- Methods
 Both therapeutic plasmapheresis (plasma-exchange [PEX]) 
and cascade filtration can be used in hypertriglyceridaemic 
pancreatitis11-13. Comparing methods, the removal rate of 
triglycerides and chylomicrons is higher with plasma-exchange 
than with cascade filtration.
- Treatment frequency
 Usually a single therapeutic plasmapheresis or cascade filtration 
is sufficient to lower triglyceride levels and to improve a 
patient's clinical profile. The treatment should be started 
immediately after the symptoms of acute pancreatitis appear. 
In some cases a second treatment within 24 to 48 hours is 
recommended.
- Treatment volume
 1-1.5 plasma volumes.
- Anticoagulants
 Many studies used ACD-A. Some authors suggest the use of 
heparin as it induces the release of lipoproteinlipase from the 
endothelium, increasing the removal of triglycerides. On the 
other hand, heparin could worsen pancreatic haemorrhages 
and, therefore, its administration is much debated and still 
controversial.
- Substitution fluids
 Albumin is frequently used as well as fresh frozen plasma as 
its lipoproteinlipase content would enhance the removal of 
triglycerides.
Discussion and conclusions
The conclusions of the first two Italian Consensus 
Conferences on LDL apheresis are presented here. The 
treatment of patients with severe dyslipidaemia is a fast 
evolving field. It is, therefore, necessary to update the 
guidelines continuously. This article is a review and 
summary of the most relevant aspects of the 1st and the 
2nd Italian Consensus Conferences on LDL-apheresis 
(1990-2009). Synoptic tables with statements that can 
be used in clinical practice are presented. The statements 
Table V - Paediatric LDL-apheresis: indications and 
recommendations - 2nd Italian Consensus 
Conference on LDL-apheresis (2009).
- Before starting LDL-apheresis refractoriness to diet and 
combined cholesterol-lowering drugs (at reasonably high 
doses) must be proven; diagnosis and complete cardiovascular 
examination (including catetherisation) must be done.
- Begin LDL-apheresis between 6 and 7 years of age (or 
before); a delay in starting LDL-apheresis (8-9 years) leads 
to the onset and progression of aortic valve disease.
- Treatment with LDL-apheresis imposes achievement of the 
therapeutic target (low density lipoprotein cholesterol <70 
mg/dL - ATP III) in children at high cardiovascular risk.
- Adverse reactions
 Collateral effects of paediatric LDL-apheresis are rare if the 
procedure is carried out by a team of experts (understanding 
that apheresis doctors for adults are not necessarily experts in 
treating children).
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Table VIII - National Lipid Association criteria for consideration of LDL-apheresis (adapted with permission from Jacobson 
et al., J Clin Lipidol 2014)6.
NLA criteria from expert panel on FH FDA-approved indication
LDL-apheresis may be considered for the following patients who, after 
6 months, do not have an adequate response to maximum tolerated 
drug therapy:
- Functional homozygous FH with LDL-C ≥300 mg/dL (or non-HDL-C 
≥330 mg/dL).
- Functional heterozygous FH with LDL-C ≥300 mg/dL (or non-
HDL-C ≥330 mg/dL) and no or one risk factor.
- Functional heterozygous FH with LDL-C ≥200 mg/dL (or non-
HDL-C ≥230 mg/dL) and high risk characteristics, such as two risk 
factors or high lipoprotein (a) ≥50 mg/dL using an isoform insensitive 
assay.
- Functional heterozygous FH with LDL-C ≥160 mg/dL (or non-
HDL-C $190 mg/dL) and very high risk characteristics (established 
CHD, other cardiovascular disease, or diabetes).
LDL-apheresis is considered medically necessary when patients 
have failed diet and maximum drug therapy from at least two 
separate classes of lipid-lowering drugs for at least 6 months in 
addition to any one of the following criteria:
- Homozygous FH with LDL-C ≥500 mg/dL.
- Heterozygous FH with LDL-C ≥300 mg/dL.
- Functional heterozygous FH with LDL-C ≥200 mg/dL in 
patients with coronary artery disease.
CHD: coronary heart disease; FDA: Food and Drug Administration; FH: familial hypercholesterolaemia; LD: low-density lipoprotein; LDL-C: low-density 
lipoprotein cholesterol; NLA: National Lipid Association; non-HDL-C: non-high-density lipoprotein cholesterol.
reported reflect the available evidence and were made 
according to objective criteria. 
Recent international updates on the management of 
dyslipidaema include guidance on the use of lipoprotein 
apheresis. For example, the National Lipid Association 
(NLA) recommendations for the management of 
dyslipidaemia include, for the first time in the USA, a 
statement that LDL-apheresis may be considered "For 
selected patients with severe hypercholesterolemia"6. 
Table VIII shows the NLA Expert Panel on FH criteria 
for consideration of LDL-apheresis, together with 
the Food and Drug Administration (FDA)-approved 
indication. The authors noted that the NLA criteria 
are more inclusive than the FDA-approved indication 
criteria, which has potential implications for clinicians 
with regards to reimbursement.
A recent position paper on homozygous FH by 
a Consensus Panel of the European Atherosclerosis 
Society also recommended that, where available, 
lipoprotein apheresis is an important adjunctive 
treatment for homozygous FH7. Specifically, the 
Consensus Panel recommended that lipoprotein 
apheresis should be initiated as early as possible, ideally 
before the age of 5 years and not later than the age of 
8 years, but acknowledged that "this and the frequency 
of treatment represent a compromise between access to 
centres, the severity of the disease, affordability, and 
the patient's choice"7. 
Recent developments in relation to the novel lipid-
lowering agents are promising and suggest the need 
for new studies to investigate forms of combination 
treatment with lipoprotein apheresis. A number of 
novel agents with different mechanisms of action may 
offer further treatment options for patients with severe 
dyslipidaemia, including homozygous FH (Table IX). 
Lomitapide, an oral inhibitor of microsomal 
triglyceride transport protein (MTP), is approved for 
use in 35 countries, including the European Union, 
the USA, Canada, Mexico, Taiwan and Israel, as an 
adjunct to a low-fat diet and other lipid-lowering 
therapies including LDL-apheresis, in the treatment of 
patients with homozygous FH8,9. When added to a low-
fat diet and ongoing standard lipid-lowering treatment 
including apheresis, lomitapide has been shown to 
significantly reduce LDL-cholesterol in adult patients 
with homozygous FH to a similar extent irrespectively 
of whether or not the patient is receiving concomitant 
apheresis10. Mipomersen, an injectable antisense 
inhibitor of apo B synthesis is approved in the USA 
as an adjunct to lipid-lowering medications and diet in 
patients with homozygous FH but its use as an adjunct 
to LDL-apheresis is not currently recommended11.
Proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors have been shown to be effective 
in the treatment of FH12,13. Evolocumab, a monoclonal 
antibody to PCSK9, was recently approved by the 
European Commission for the treatment of patients 
with homozygous FH, hypercholesterolaemia and 
mixed dyslipidaemia, including those on apheresis14. 
Another PCSK9 inhibitor, alirocumab, is approved for 
use in the USA and the European Union as an adjunct 
to diet and statin therapy for adults with heterozygous 
FH or clinical atherosclerotic cardiovascular disease, 
who require additional lowering of LDL-cholesterol15. 
The prescribing information for alirocumab does not 
specifically mention its use in patients undergoing 
apheresis15. At least for now, there is no specific clinical 
trigger for adding these agents to apheresis, and clinical 
decisions of this type lie between the doctor and the 
patient. 
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When considering any new therapeutic approach, 
it will be important to take into account the effects of 
the various novel lipid-lowering agents not only on 
plasma lipid and lipoprotein levels, but also on the 
endothelium and on inflammation in general. Recent 
studies have suggested that lipoprotein apheresis may 
favourably influence regression of atherosclerotic 
lesions through effects unrelated to the extracorporeal 
removal of lipoproteins, such as the decrease of 
inflammatory mediators16-18. In some cases firm 
conclusions are difficult to draw, but the available 
evidence, although limited, remains the only concrete 
conclusion that can guide the clinician. Our concern is 
that the lack of collaboration between medical device 
and pharmaceutical companies will greatly affect the 
real opportunities of conducting studies in this field as 
the overwhelming cost of such studies is beyond the 
reach of investigators. Nevertheless, the most evident 
conclusion is that appropriate therapy in the patient 
with severe dyslipidaemia is one that reduces LDL-
cholesterol and Lp(a) and thwarts the development 
of atherosclerotic lesions leading to severe ischaemic 
complications. For the aforementioned reasons we have 
developed this set of recommendations to guide the 
experts who take care of patients deserving a correct, 
continuous and combined therapeutic approach. These 
recommendations, together with recent international 
statements on the management of dyslipidaemia, 
provide clinicians with guidance on which patients are 
most likely to benefit from lipoprotein apheresis. As 
different centres use different apheresis techniques and 
schedules, a European Consensus statement providing 
further detailed guidance on the use of specific apheresis 
techniques and treatment protocols, including their use 
in combination with different pharmacotherapies, would 
be of great value in the future.
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